Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 μg ethinylestradiol and 150 μg levonorgestrel: A randomized trial

Human Reproduction

Volumn 20, Issue 2, 2005, Pages 557-562

  Oddsson, K ^a   Leifels Fischer, B ^b   Wiel Masson, D ^c   de Melo, N R ^d   Benedetto, C ^e   Verhoeven, C H J ^f   Dieben, Thom O M ^f  

^a Women's Health Associates   (Iceland)

^b São Paulo University ^*  (Germany)

^c University of Turin ^*  (France)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF TURIN   (Italy)

^f NV ORGANON   (Netherlands)

Author keywords

Contraceptive; Cycle control; Irregular bleeding; NuvaRing; Superiority

Indexed keywords

ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BELGIUM; BRAZIL; BREAKTHROUGH BLEEDING; CHILE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DRUG EFFICACY; DRUG SAFETY; FEMALE; FINLAND; FRANCE; GERMANY; HUMAN; HUMAN EXPERIMENT; INCIDENCE; ITALY; MENSTRUAL CYCLE; MULTICENTER STUDY; NORMAL HUMAN; NORWAY; OPEN STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SPAIN; SPOTTING; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SWEDEN; VAGINA RING;

EID: 14044278206     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/deh604     Document Type: Article

References (16)

1. Åkerlund M, Røde A and Westergaard J (1993) Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br J Obstet Gynaecol 100,832-838.
2. Archer DF, Maheux R, DelConte A and O'Brien FB (1999) Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). Am J Obstet Gynecol 181,39-44.
3. Bjarnadóttir RI, Tuppurainen M and Killick SR (2002) Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinylestradiol. Am J Obstet Gynecol 186,389-395.
4. Dieben TO, Roumen FJ and Apter D (2002) Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 100,585-593.
5. Endrikat J, Cronin M, Gerlinger C, Ruebig A, Schmidt W and Dusterberg B (2001a) Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 microg ethinylestradiol and 75 microg gestodene. Contraception 64,99-105.
6. Endrikat J, Cronin M, Gerlinger C, Ruebig A, Schmidt W and Dusterberg B (2001b) Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinylestradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinylestradiol and 150 microg desogestrel. Contraception 64,201-207.
7. Gestodene Study Group 322 (1999) The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 μg and ethinylestradiol 15 μg. Eur J Contracept Reprod Health Care 4,9-15.
8. Gestodene Study Group 324 (1999) Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 μ and ethinylestradiol 15 μg and a 21-day regimen of desogestrel 150 μg/ethinylestradiol 20 μg. Eur J Contracept Reprod Health Care 4,17-24.
9. Kaunitz AM (1998) Oral contraceptive oestrogen dose considerations. Contraception 58,15S-21S.
10. Novák A, de la Loge C, Abetz L and van der Meulen EA (2003) The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception 67,187-194.
11. Reisman H, Martin D and Gast MJ (1999) A mutlicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 microg levonorgestrel with 20 microg ethinylestradiol or triphasic norethindrone with ethinylestradiol. Am J Obstet Gynecol 181,45-52.
12. Rosenberg MJ and Waugh MS (1998) Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 179,577-582.
13. Rosenberg MJ and Waugh MS (1999) Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol 180,276-279.
14. Rosenberg MJ, Waugh MS and Meehan TE (1995) Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 51,283-288.
15. Rosenberg MJ, Meyers A and Roy V (1999) Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms oestrogen preparations. Contraception 60,321-329.
16. Roumen FJ, Apter D, Mulders TM and Dieben TO (2001) Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 16,469-475.